Form 4: HALO Director Sells Shares Under 10b5-1 Plan

HALOZYME THERAPEUTICS Director Bernadette Connaughton sold 2,000 shares of common stock for $70.25 per share, executed under a pre-arranged 10b5-1 trading plan.

Summary

• Bernadette Connaughton, a Director of HALOZYME THERAPEUTICS, INC. (HALO), reported a sale of common stock.
• The transaction involved the disposition of 2,000 shares of common stock.
• The shares were sold at a price of $70.25 per share.
• The transaction date was January 5, 2026.
• Following this transaction, Ms. Connaughton beneficially owns 40,123 shares of common stock directly.
• The sale was executed pursuant to a Rule 10b5-1 trading plan adopted on May 29, 2025.

Sentiment

Score: 5

Explanation: The filing reports a routine, pre-scheduled insider stock sale under a 10b5-1 plan, which is generally considered a neutral event and does not inherently indicate positive or negative sentiment regarding the company's future prospects.

Future Outlook

The filing does not contain any forward-looking statements or guidance regarding the company's future outlook.

Industry Context

This Form 4 filing reports a routine insider transaction and does not provide information directly related to broader industry trends or competitive landscape.

Stakeholder Impact

• Shareholders: The sale represents a minor, pre-planned divestment by a director, which is unlikely to have a significant impact on shareholder sentiment or the company's operational performance.

Key Dates

Keywords

HALOZYME THERAPEUTICS, HALO, Insider Trading, Form 4, Stock Sale, 10b5-1 Plan, Bernadette Connaughton, Director